Press Releases Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Real-time Estimate Cboe BZX Other stock markets 11:17:58 2024-04-29 am EDT			5-day change	1st Jan Change
1.585 ^USD	+0.32%		-7.31%	+3.59%

04:43pm	Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire	MT
Apr. 22	Transcript : Lexicon Pharmaceuticals, Inc. - Analyst/Investor Day

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals	09:01am	AQ
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024	07:01am	AQ
Lexicon Pharmaceuticals to Host 2024 Investor Day	Apr. 18	AQ
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	AQ
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo	Mar. 25	AQ
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease	Mar. 12	AQ
Lexicon: Q4 Earnings Snapshot	Mar. 11	AQ
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update	Mar. 11	AQ
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities	Mar. 11	AQ
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA	Mar. 11	AQ
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08	AQ
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference	Dec. 21	AQ
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)	Nov. 30	AQ
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference	Nov. 22	AQ
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data	Nov. 12	AQ
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference	Nov. 10	AQ
Lexicon: Q3 Earnings Snapshot	Nov. 08	AQ
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 08	AQ
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023	Nov. 03	AQ
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023	Nov. 02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Press Releases

Filters